News

The new company, Afimmune, will continue the clinical development of DS102, a novel, anti-fibrotic compound. The company will study DS102 in NASH in addition to certain pulmonary disorders.

The approval of the sNDA is tentative because the FDA has determined that the drug meets all of the required quality, safety, and efficacy standards for approval, but

The Board consists of William Mitchell, M.D., Ph.D., Ronald Brus, M.D., W. Neal Burnette, Ph.D., and Christopher Nicodemus, M.D., F.A.C.P. Dr. Mitchell, M.D., Ph.D., Chairman of the Board

The JV, which was initially announced in December 2015, will focus on the discovery, development and commercialization of new therapeutics to treat blood disorders, blindness, and congenital heart

Scientists at the Rockefeller University and the La Jolla Institute for Allergy and Immunology found evidence that suggests adult brain cells critical to learning and memory might be

Aquatrove is a Chicago based biotechnology company with focus on human reproductive health and fertility products. Through the deal, the Brussels, Belgium headquartered company will acquire Aquatrove’s international

The company will invest the amount over ten years to expand the site for the continued manufacturing of generic injectable medicines.  Fresenius Kabi plans to break the ground

RBP-6000 is an investigational buprenorphine sustained-release formulation, which uses the company’s Atrigel delivery system Indivior said if granted marketing authorization in the US, the drug will provide a

The most significant is new technology for Direct Clinical Document Architecture (CDA) Automation of reporting to the Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network